Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPD-52520
- Development stage
- Unknown
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intranasal
01
Overview
IPD-52520 is an engineered mini-protein prophylaxis candidate developed by IAVI in collaboration with the Institute for Protein Design (IPD) at the University of Washington and GSK. Designed through computational methods, the protein is intended to bind specifically to the SARS-CoV-2 virus to neutralize it and block its entry into host cells. Administered as a nasal spray, it creates a protective layer in the upper respiratory tract to prevent viral penetration and may alleviate symptoms of existing infections by disrupting viral replication. Development has been supported by the Bill & Melinda Gates Foundation, with clinical evaluation including a Phase 1 trial (IAVI C106) in South Africa and Zimbabwe.
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on IPD-52520.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPD-52520.